Formycon · ISIN: DE000A1EWVY8

EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel

EQS-News: Formycon AG / Key word(s): Agreement Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel 13.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // Janu...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 13.01.2025 | 07:00
13 January 2025 07:00AM
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Formycon AG / Key word(s): Agreement Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel 13.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // Janu...
© EQS Newswire
09 January 2025 03:30PM
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon included in TecDAX Index of Deutsche Börse 09.01.2025 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 9, 2025   Formycon included in TecDAX Index of Deutsche Börse Formycon to join the ranks...
© EQS Newswire
08 January 2025 02:30PM
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 8, 2025...
© EQS Newswire
11 December 2024 04:26PM
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 11.12.2024 / 16:25 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer...
© EQS Newswire
09 December 2024 06:30AM
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
EQS-News: Formycon AG / Key word(s): Agreement MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region 09.12.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // December 09, 2024   MS Pharma becomes Partner for the Comm...
© EQS Newswire
05 December 2024 12:55PM
EQS-News: Formycon joins the SDAX of the German Stock Exchange
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon joins the SDAX of the German Stock Exchange 05.12.2024 / 12:55 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // December 5, 2024 Formycon joins the SDAX of the German Stock Exchange Formycon shares will be pa...
© EQS Newswire
28 November 2024 06:30AM
EQS-News: Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
EQS-News: Formycon AG / Key word(s): 9 Month figures/Quarterly / Interim Statement Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes 28.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // Novembe...
© EQS Newswire
19 November 2024 06:30AM
EQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): 9 Month figures/Conference Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences 19.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // Novembe...
© EQS Newswire
18 November 2024 06:30AM
EQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
EQS-News: Formycon AG / Key word(s): Statement/Regulatory Admission Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Re...
© EQS Newswire
15 November 2024 06:18PM
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
EQS-Ad-hoc: Formycon AG / Key word(s): Statement/Regulatory Admission Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA 15-Nov-2024 / 18:18 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG....
© EQS Newswire
11 November 2024 05:41PM
EQS-News: Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
EQS-News: Formycon AG / Key word(s): Personnel/Contract Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard 11.11.2024 / 17:41 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // Novem...
© EQS Newswire
04 November 2024 06:30AM
EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
EQS-News: Formycon AG / Key word(s): Regulatory Admission/IPO Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange 04.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 04, 2024 Formycon applies for admission to th...
© EQS Newswire
16 October 2024 06:50AM
EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
EQS-News: Formycon AG / Key word(s): Scientific publication/Study results Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D 16.10.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement....
© EQS Newswire
01 October 2024 05:06PM
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 01.10.2024 / 17:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer...
© EQS Newswire
30 September 2024 07:30AM
EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Market Launch Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) 30.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // September 30, 2024 Formycon and Fresenius...
© EQS Newswire
27 September 2024 09:56PM
EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
EQS-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) 27-Sep-2024 / 21:56 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely res...
© EQS Newswire
27 September 2024 09:00AM
EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Miscellaneous Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases 27.09.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement....
© EQS Newswire
17 September 2024 06:50AM
EQS-News: Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
EQS-News: Formycon AG / Key word(s): Conference Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna 17.09.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // September...
© EQS Newswire
17 September 2024 06:50AM
EQS-News: Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
EQS-News: Formycon AG / Key word(s): Conference Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna 17.09.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // September...
© EQS Newswire
19 August 2024 02:11PM
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 19.08.2024 / 14:10 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer...
© EQS Newswire
13 August 2024 06:50AM
EQS-News: Formycon reports a strong first half-year with multiple milestones achieved
EQS-News: Formycon AG / Key word(s): Half Year Results/Half Year Report Formycon reports a strong first half-year with multiple milestones achieved 13.08.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // August 13, 2024 Formycon reports a strong first half-...
© EQS Newswire
07 August 2024 06:50AM
EQS-News: Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Half Year Results/Conference Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences 07.08.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // August 7...
© EQS Newswire
06 August 2024 12:40PM
EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
EQS-Ad-hoc: Formycon AG / Key word(s): Preliminary Results/Forecast Formycon AG increases its outlook for the 2024 fiscal year 06-Aug-2024 / 12:40 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible fo...
© EQS Newswire
30 July 2024 06:50AM
EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
EQS-News: Formycon AG / Key word(s): Study Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206 30.07.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // July 30, 2024   Formycon announces start of clinical phase III...
© EQS Newswire
26 July 2024 12:00PM
EQS-News: Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
EQS-News: Formycon AG / Key word(s): Statement/Regulatory Admission Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara® 26.07.2024 / 12:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // July 26, 2024  ...
© EQS Newswire
26 July 2024 10:54AM
EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
EQS-Ad-hoc: Formycon AG / Key word(s): Statement/Regulatory Admission Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA 26-Jul-2024 / 10:54 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. T...
© EQS Newswire
01 July 2024 06:50AM
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2) 01.07.2024 / 06:50 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // July 01, 2024   Formycon receives FDA approv...
© EQS Newswire
28 June 2024 11:50PM
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) 28-Jun-2024 / 23:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely...
© EQS Newswire
28 June 2024 11:50PM
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) 28-Jun-2024 / 23:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely...
© EQS Newswire
13 June 2024 03:30PM
EQS-News: Formycon reports on the results of the Annual General Meeting
EQS-News: Formycon AG / Key word(s): AGM/EGM/Miscellaneous Formycon reports on the results of the Annual General Meeting 13.06.2024 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // June 13, 2024 Formycon reports on the results of the Annual General Meeting Man...
© EQS Newswire
13 June 2024 10:41AM
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Original-Research: Formycon AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Formycon AG Company Name: Formycon AG ISIN: DE000A1EWVY8 Reason for the research: Update Recommendation: Buy from: 13.06.2024 Target price: €80,00 Target price on sight of: 12 months Last rating change: - Analyst: Simon Sc...
© EQS Newswire
13 June 2024 07:31AM
EQS-News: Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
EQS-News: Formycon AG / Key word(s): Study/Miscellaneous Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda 13.06.2024 / 07:31 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // June 13, 2024 Form...
© EQS Newswire
15 May 2024 07:30AM
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
EQS-News: Formycon AG / Key word(s): Agreement MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region 15.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // May 15, 2024  ...
© EQS Newswire
15 May 2024 07:30AM
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
EQS-News: Formycon AG / Key word(s): Agreement MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region 15.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // May 15, 2024  ...
© EQS Newswire
08 May 2024 07:30AM
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
EQS-News: Formycon AG / Key word(s): Quarterly / Interim Statement/Quarter Results Formycon reports on successful operating business and financial figures for the first quarter of 2024 08.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // May 8, 2024 Form...
© EQS Newswire
07 May 2024 11:00AM
EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon AG / Key word(s): AGM/EGM/Personnel Formycon invites to the Annual General Meeting on June 12, 2024 in Munich 07.05.2024 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // 07 May 2024 Formycon invites to the Annual General Meeting on June 12,...
© EQS Newswire
02 May 2024 07:30AM
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon AG / Key word(s): Quarterly / Interim Statement/Conference Formycon hosts conference call on the results of the first quarter 2024 02.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // May 02, 2024 Formycon hosts conference call on the...
© EQS Newswire
25 April 2024 07:30AM
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance 25.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April...
© EQS Newswire
22 April 2024 07:30AM
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Formycon AG / Key word(s): Conference/Annual Results Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 22.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of t...
© EQS Newswire
12 April 2024 10:15PM
EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQS-News: Formycon AG / Key word(s): Preliminary Results/Forecast Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast 12.04.2024 / 22:15 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // 12 April 2024  ...
© EQS Newswire
12 April 2024 07:27PM
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQS-Ad-hoc: Formycon AG / Key word(s): Preliminary Results/Forecast Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year 12-Apr-2024 / 19:27 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service o...
© EQS Newswire
11 April 2024 07:30AM
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
EQS-News: Formycon AG / Key word(s): Market Launch Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) 11.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April 11, 2024   Formycon announces c...
© EQS Newswire
18 March 2024 10:00AM
EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
EQS-News: Formycon AG / Key word(s): Agreement Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada 18.03.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // March 18, 2024   Formycon and Fre...
© EQS Newswire
11 March 2024 07:30AM
EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Market Launch FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region 11.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // March 11, 2024   FYB201/Ranibizumab keep...
© EQS Newswire
29 January 2024 10:15PM
EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment
EQS-News: Formycon AG / Key word(s): Capital Increase Gedeon Richter becomes strategic investor of Formycon via equity investment 29.01.2024 / 22:15 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 29, 2024 Gedeon Richter becomes strategic investor of Formycon...
© EQS Newswire
29 January 2024 10:10PM
EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
EQS-Ad-hoc: Formycon AG / Key word(s): Corporate Action/Capital Increase Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor 29-Jan-2024 / 22:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, tr...
© EQS Newswire
18 January 2024 07:30AM
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
EQS-News: Formycon AG / Key word(s): Market Report Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023 18.01.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 18, 2024   Formycon Rani...
© EQS Newswire
04 January 2024 05:06PM
EQS-News: Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Formycon AG / Key word(s): Conference Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference 04.01.2024 / 17:06 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 04, 2024   Formycon to present at the 42nd Annual J.P. Morgan Healthcar...
© EQS Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.